Amniotic Membrane Market - By Product, By Application, By End Use – Global Forecast, 2024 – 2032

The industry was valued at approximately USD 1.7 billion in 2023 and is estimated to grow at a 7.9% CAGR from 2024 to 2032, driven by its regenerative properties and applications in medical treatments and surgeries.

The cryopreserved segment is forecasted to reach USD 1.7 billion by 2032 due to its extensive use in various medical disciplines, such as ophthalmology, where it treats corneal defects, promotes faster healing, and reduces inflammation and scarring.

The U.S. market is projected to reach USD 1.1 billion by 2032, driven by well-established healthcare facilities, leading industry players, a focus on regenerative medicine, and the rapid adoption of advanced technologies.

Prominent participants include Amnio Technology, LLC, Applied Biologics LLC, BioTissue Holdings Inc., Celularity Inc., Corza Health, Inc., Integra LifeSciences Holdings Corporation, MiMedx Group, Inc., Organogenesis Holdings Inc., Skye Biologics, Inc., and Smith & Nephew plc.